In a massive stride towards Alzheimer's treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer's patients.

This breakthrough is a beacon of hope for millions affected by this debilitating disease, known for its profound impact on cognitive function and behavioral symptoms.

The compelling findings were discussed at Benzinga's Healthcare Summit, where Ram Mukunda, IGC Pharma CEO, and Claudia Grimaldi, IGC Pharma vice president, director, chief commercial officer and principal finance officer, delved into the intricacies of Alzheimer's and the innovative approach the company's...